Health Highlights: April 24, 2023
Combo therapy may prevent cancer ' s return after liver surgery. Atezolizumab and bevacizumab are already used together to treat advanced liver cancer, now a new study finds it does the same for early-stage disease. Read more
This is your brain on... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 24, 2023 Category: General Medicine Source Type: news
AACR: Adjuvant Atezolizumab + Bevacizumab Beneficial in Liver Cancer
TUESDAY, April 18, 2023 -- For patients with high-risk hepatocellular carcinoma (HCC), adjuvant therapy of atezolizumab with bevacizumab (atezo + bev) prolongs recurrence-free survival, according to a study presented at the annual meeting of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 18, 2023 Category: Pharmaceuticals Source Type: news
Drug Combo Improves Recurrence-Free Survival After HCC Resection Drug Combo Improves Recurrence-Free Survival After HCC Resection
The atezolizumab-bevacizumab combination is the first to show efficacy in the adjuvant setting after HCC resection for patients at high risk for recurrence, but the overall survival benefit is unclear.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 18, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Roche ’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
Discussions with health authorities are ongoing and follow-up will continue for the final RFS data and more mature OS data at the next planned analysis.The IMbrave050 study is part of Roche ’s overall commitment to drive fundamental treatment change and improve outcomes for people living with liver cancer. Tecentriq plus Avastin was the first treatment in over a decade to significantly improve OS over the existing standard of care, based on data from the IMbrave150 study.3 The Tecentriq combination quickly became a standard of care in unresectable HCC and is clearly defined as a preferred front-line treatment in multiple...
Source: Roche Media News - April 16, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
Discussions with health authorities are ongoing and follow-up will continue for the final RFS data and more mature OS data at the next planned analysis.The IMbrave050 study is part of Roche ’s overall commitment to drive fundamental treatment change and improve outcomes for people living with liver cancer. Tecentriq plus Avastin was the first treatment in over a decade to significantly improve OS over the existing standard of care, based on data from the IMbrave150 study.3 The Tecentriq combination quickly became a standard of care in unresectable HCC and is clearly defined as a preferred front-line treatment in multiple...
Source: Roche Investor Update - April 16, 2023 Category: Pharmaceuticals Source Type: news
Genentech ending commercial manufacturing, 265 jobs at 40-year-old South S.F. facility
The facility that produced the Genentech-defining cancer drugs Avastin and Herceptin as well as 10 others is stopping commercial manufacturing. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 23, 2023 Category: American Health Authors: Ron Leuty Source Type: news
USFDA issues CRL for Bevacizumab license application moved by Viatris: Biocon
"The USFDA has issued a CRL for the Biologics License Application (BLA) for Bevacizumab filed by our partner Viatris (Mylan)," a company spokesperson said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 12, 2023 Category: Pharmaceuticals Source Type: news
No Survival Benefit for Upfront VEGF Inhibitors in Metastatic CRC No Survival Benefit for Upfront VEGF Inhibitors in Metastatic CRC
In fact, the worst survival outcomes were seen with the most commonly used first-line regimen, FOLFOX chemotherapy plus the VEGF inhibitor bevacizumab.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 6, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLunsumio (follicular lymp...
Source: Roche Investor Update - February 2, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Basel, 2 February 2023Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLun...
Source: Roche Media News - February 2, 2023 Category: Pharmaceuticals Source Type: news
New Standard of Care for Refractory Metastatic Colorectal Cancer
(MedPage Today) -- SAN FRANCISCO -- Survival in treatment-refractory metastatic colorectal cancer (mCRC) improved by more than 3 months in patients who received bevacizumab (Avastin) in addition to chemotherapy, a randomized trial showed.
Median... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 23, 2023 Category: Gastroenterology Source Type: news
SUNLIGHT: New Standard of Care in Refractory Metastatic CRC SUNLIGHT: New Standard of Care in Refractory Metastatic CRC
The SUNLIGHT trial results show that adding bevacizumab to trifluridine/tipiracil (Lonsurf) improves median overall and progression free survival without increasing the risk for serious adverse events.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 23, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Investor Update - January 19, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Media News - January 19, 2023 Category: Pharmaceuticals Source Type: news
Atezolizumab Plus Bevacizumab: A New Standard for Some NSCLC? Atezolizumab Plus Bevacizumab: A New Standard for Some NSCLC?
Encouraging findings with the combination suggest that it could offer a new standard treatment for patients with highly mutated non –small cell lung cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 28, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
